A Cost Effectiveness and Capacity Analysis for the Introduction of Universal Rotavirus Vaccination in Kenya: Comparison Between Rotarix and RotaTeq Vaccines

The authors of this article, published in PLoS ONE, applied cost-effectiveness modeling and a cold-chain impact assessment to aid decision-making on rotavirus vaccine introduction in Kenya. They conclude that use of either vaccine is cost-effective, but Rotarix is more cost-effective and has preferable packaging and presentation.

Author(s): van Hoek AJ, Ngama M, Ismail A, et al.

Published: 2012

  • Visit web page (English)

    (Located at www.plosone.org)

    Citation: van Hoek AJ, Ngama M, Ismail A, et al. A Cost Effectiveness and Capacity Analysis for the Introduction of Universal Rotavirus Vaccination in Kenya: Comparison Between Rotarix and RotaTeq Vaccines. PLoS ONE. 2012;7(10):e47511.